Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels.
نویسندگان
چکیده
Given the increased prevalence of cardiovascular disease in the world, the search for genetic variations that impact risk factors associated with the development of this disease continues. Multiple genetic association studies demonstrate that procollagen C-proteinase enhancer 2 (PCPE2) modulates HDL levels. Recent studies revealed an unexpected role for this protein in the proteolytic processing of pro-apolipoprotein (apo) A-I by enhancing the cleavage of the hexapeptide extension present at the N-terminus of apoA-I. To investigate the role of the PCPE2 protein in an in vivo model, PCPE2-deficient (PCPE2 KO) mice were examined, and a detailed characterization of plasma lipid profiles, apoA-I, HDL speciation, and function was done. Results of isoelectric focusing (IEF) electrophoresis together with the identification of the amino terminal peptides DEPQSQWDK and WHVWQQDEPQSQWDVK, representing mature apoA-I and pro-apoA-I, respectively, in serum from PCPE2 KO mice confirmed that PCPE2 has a role in apoA-I maturation. Lipid profiles showed a marked increase in plasma apoA-I and HDL-cholesterol (HDL-C) levels in PCPE2 KO mice compared with wild-type littermates, regardless of gender or diet. Changes in HDL particle size and electrophoretic mobility observed in PCPE2 KO mice suggest that the presence of pro-apoA-I impairs the maturation of HDL. ABCA1-dependent cholesterol efflux is defective in PCPE2 KO mice, suggesting that the functionality of HDL is altered.
منابع مشابه
Cubbing in proapolipoprotein maturation.
Journal of Lipid Research Volume 52, 2011 1861 Copyright © 2011 by the American Society for Biochemistry and Molecular Biology, Inc. In this issue of the Journal of Lipid Research , Francone and colleagues ( 1 ) have described an interesting HDL phenotype in a mouse defi cient in procollagen proteinase enhancer 2 (PCPE2). Present in the plasma of the mice are pre HDL containing as its major, if...
متن کاملRegulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.
Given the increased prevalence of cardiovascular disease in the world, the search for genetic variations controlling the levels of risk factors associated with the development of the disease continues. Multiple genetic association studies suggest the involvement of procollagen C-proteinase enhancer-2 (PCPE2) in modulating HDL-C levels. Therefore biochemical and mechanistic studies were undertak...
متن کاملMaturation of apolipoprotein A-I: unrecognized health benefit or a forgotten rudiment?
Apolipoprotein A-I (apoA-I) is the principal protein of high density lipoprotein and is most likely responsible for many, if not all, of HDLʼs antiatherogenic properties. In humans, apoA-I is synthesized in hepatocytes and enterocytes as a prepro-protein. The 18 amino acid prepeptide is cleaved prior to secretion and pro-apoA-I is secreted and processed into mature protein in blood or lymph; th...
متن کاملInhibition of endothelial lipase causes increased HDL cholesterol levels in vivo.
Endothelial lipase (EL) is a recently discovered member of the lipoprotein lipase gene family that hydrolyzes HDL phospholipids ex vivo and reduces HDL cholesterol (HDL-C) levels when overexpressed in vivo in mice. To gain further insight into the physiological role of EL in the metabolism of HDL in vivo, studies were performed in which EL was inhibited in wild-type, hepatic lipase knockout (HL...
متن کاملWhat does procollagen C-endopeptidase enhancer protein 2 have to do with HDL-cholesteryl ester uptake? Or how I learned to stop worrying and love reverse cholesterol transport?
PURPOSE OF REVIEW The purpose of this study is to provide an update on the role HDL apolipoprotein A-I plays in reducing the risk of cardiovascular disease (CVD) and how it relates to reverse cholesterol transport (RCT). RECENT FINDINGS Despite numerous studies showing that plasma HDL cholesterol concentrations are correlated with a reduced risk of CVD, pharmacologic elevation of HDL has not ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of lipid research
دوره 52 11 شماره
صفحات -
تاریخ انتشار 2011